Introduction
Interleukin-1 receptor antagonist (IL-1RA) functions as a competitive inhibitor of IL-1α and IL-1β binding to the IL-1 type 1 receptor with an affinity equal to IL-1β without any agonist activity (Arend et al., 1990; Dripps et al., 1991; Hannum et al., 1990) . In doing so, IL-1RA prevents IL-1 activation of pro-inflammatory signal transduction proteins such as NFκB and AP-1 (Dinarello, 1997) and subsequent pro-inflammatory immune responses (Weber et al., 2011) .
Intracerebral administration of IL-1RA has been shown to reliably block the induction of sickness responses by IL-1β or LPS (Bluthe et al., 1992; Cartmell et al., 1999; Kent et al., 1992; Luheshi et al., 1996; Opp and Krueger, 1991) . In these experiments the proinflammatory stimulus was administered concurrently with, or immediately before, the intracerebral IL-1RA treatment, and proinflammatory effects were measured within hours of treatment. Also, intracerebral administration of IL-1RA attenuates aginginduced sensitization of neuroinflammatory and sickness responses to LPS (Abraham and Johnson, 2009 ). Interestingly, Abraham and Johnson (2009) found that exogenous IL-1RA exerted antiinflammatory effects in aged mice 24 h post-IL-1RA administration. This finding is particularly noteworthy because the duration of IL-1RA effects on neuroinflammation (24 h) far exceeded the plasma half-life (b2 h) of IL-1RA. Plasma IL-1RA levels decline rapidly after intra-venous infusion and exhibit an initial half-life b30 min and a terminal half-life b2 h (Granowitz et al., 1992) . Notably, systemic administration of IL-1RA results in detectable levels in brain and CSF up to 18 h post-injection and was neuroprotective against cerebral ischemia (Cawthorne et al., 2011; Greenhalgh et al., 2010) . We conducted a study in which a single dose of IL-1RA was administered intra-cisterna magna (ICM) in aged rats concurrent with a peripheral administration of Escherichia coli. E. coli given to aging rats typically produces impairments in memory of new learning occurring 4 d later, as well as producing persistent neuroinflammation still present at 4 d. Four days after IL-1RA and E. coli administration, IL-1RA treatment blocked these memory deficits and neuroinflammatory effects (Frank et al., 2010) . One possible explanation for the prolonged antiinflammatory effects of IL-1RA administration in the CNS is that IL-1RA bioactivity may be extended in the CNS relative to the short duration of IL-1RA action after peripheral administration. The present study explored this possibility by examining the duration of IL-1RA effects on subsequent LPS-induced neuroinflammatory processes and sickness responses after a single ICM injection of IL-1RA.
Materials and methods

Rats
Male Sprague-Dawley rats (60-90 d old; Harlan Sprague-Dawley, Inc., Indianapolis, IN, USA) were pair-housed with food and water available ad libitum. The colony was maintained at 22-23°C on a 12 h light/dark cycle (lights on at 07:00 h). All experimental procedures Journal of Neuroimmunology 252 (2012) 33-39 
